CN105582134A - Traditional Chinese medicine composition for treating prostatitis - Google Patents
Traditional Chinese medicine composition for treating prostatitis Download PDFInfo
- Publication number
- CN105582134A CN105582134A CN201610145713.6A CN201610145713A CN105582134A CN 105582134 A CN105582134 A CN 105582134A CN 201610145713 A CN201610145713 A CN 201610145713A CN 105582134 A CN105582134 A CN 105582134A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- medicine composition
- parts
- traditional chinese
- medicinal material
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003814 drug Substances 0.000 title claims abstract description 25
- 239000000203 mixture Substances 0.000 title claims abstract description 24
- 201000007094 prostatitis Diseases 0.000 title abstract description 7
- 239000008187 granular material Substances 0.000 claims abstract description 14
- 241000124033 Salix Species 0.000 claims abstract description 10
- 210000000582 semen Anatomy 0.000 claims abstract description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 28
- 229920003266 Leaf® Polymers 0.000 claims description 19
- 239000000463 material Substances 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 13
- 239000000284 extract Substances 0.000 claims description 12
- 238000003756 stirring Methods 0.000 claims description 12
- 241000563988 Turpinia Species 0.000 claims description 10
- 230000001154 acute effect Effects 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 10
- 241001116477 Adenophora triphylla Species 0.000 claims description 9
- 244000201986 Cassia tora Species 0.000 claims description 9
- 235000014552 Cassia tora Nutrition 0.000 claims description 9
- 241000446281 Eschenbachia blinii Species 0.000 claims description 9
- 235000004496 Oenothera biennis Nutrition 0.000 claims description 9
- 241000353135 Psenopsis anomala Species 0.000 claims description 9
- 239000002994 raw material Substances 0.000 claims description 9
- 239000004575 stone Substances 0.000 claims description 9
- 239000012141 concentrate Substances 0.000 claims description 8
- 241000219925 Oenothera Species 0.000 claims description 7
- 239000006071 cream Substances 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 238000007605 air drying Methods 0.000 claims description 4
- 238000009835 boiling Methods 0.000 claims description 4
- 238000004140 cleaning Methods 0.000 claims description 4
- 239000000706 filtrate Substances 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- 238000004108 freeze drying Methods 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 238000001556 precipitation Methods 0.000 claims description 4
- 239000011122 softwood Substances 0.000 claims description 4
- 229910001220 stainless steel Inorganic materials 0.000 claims description 4
- 239000010935 stainless steel Substances 0.000 claims description 4
- 238000003809 water extraction Methods 0.000 claims description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 3
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 3
- 235000011331 Brassica Nutrition 0.000 claims description 2
- 241000219198 Brassica Species 0.000 claims description 2
- 241000219929 Onagraceae Species 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims 1
- 238000005469 granulation Methods 0.000 claims 1
- 230000003179 granulation Effects 0.000 claims 1
- 108090001007 Interleukin-8 Proteins 0.000 abstract description 13
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 abstract description 12
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract description 12
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract description 12
- 230000001684 chronic effect Effects 0.000 abstract description 11
- 210000002307 prostate Anatomy 0.000 abstract description 11
- 206010061218 Inflammation Diseases 0.000 abstract description 4
- 230000004054 inflammatory process Effects 0.000 abstract description 4
- 241000567398 Dischidia chinensis Species 0.000 abstract 1
- 241000237858 Gastropoda Species 0.000 abstract 1
- 244000196929 Oenothera glazioviana Species 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 19
- 102000004890 Interleukin-8 Human genes 0.000 description 12
- 206010069918 Bacterial prostatitis Diseases 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 210000000265 leukocyte Anatomy 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000005482 chemotactic factor Substances 0.000 description 2
- 208000013507 chronic prostatitis Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 241001633583 Adenophora Species 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000208327 Apocynaceae Species 0.000 description 1
- 241000581854 Artemisia santonicum Species 0.000 description 1
- 241000459479 Capsula Species 0.000 description 1
- 241000731466 Chlorostoma Species 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 201000009495 Hypotrichosis Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241001529246 Platymiscium Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 101000648290 Rattus norvegicus Tumor necrosis factor Proteins 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 241001671215 Staphyleaceae Species 0.000 description 1
- 241000237983 Trochidae Species 0.000 description 1
- 208000012931 Urologic disease Diseases 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004705 lumbosacral region Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 210000002640 perineum Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 210000003689 pubic bone Anatomy 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000001625 seminal vesicle Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 208000014001 urinary system disease Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 201000010653 vesiculitis Diseases 0.000 description 1
- 239000008554 xiao zhi ling Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/27—Asclepiadaceae (Milkweed family), e.g. hoya
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/342—Adenophora
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/76—Salicaceae (Willow family), e.g. poplar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a traditional Chinese medicine composition for treating prostatitis and relates to the technical field of traditional Chinese medicine. The traditional Chinese medicine composition granules are prepared from radix adenophorae, semen brassicae, dischidia chinensis herb, black fovea snail, root of redsepal eveningprimrose, folium turpiniae, conyzae herb and willow leaf. The traditional Chinese medicine composition treats chronic nonbaterial prostatitis by reducing the level of TNF-alpha and IL-8 in the prostate tissue of a patient, the inflammatory reaction degree is reduced, and then repair of the prostate tissue structure is promoted.
Description
The application be applicant Shandong Weikang Biomedical Science and Technology Co., Ltd. propose application for a patent for invention (denomination of invention is: one is treated prostatitic Chinese medicine composition and application thereof, application number is: 2014104612187, the applying date is: on September 12nd, 2014) divisional application.
Technical field
The invention belongs to traditional Chinese medicine technical field, relate to one and treat prostatitic Chinese medicine composition.
Background technology
Chronic non-bacterial prostatitis is a kind of common male sex's urological diseases, and main manifestations is pelvis area pain, is found in perineum, penis, crissum portion, urethra, pubis portion and lumbosacral region position. Paruria can show as urgent urination, frequent micturition, odynuria and enuresis nocturna and increase etc. Due to chronic ache obstinate, patients ' life quality declines, and may have the symptom of sex dysfunction, anxiety, depression, insomnia, decrease of memory. Multiplex antibiotic, antalgesic are treated clinically at present, but antibiotic, antalgesic have certain side effect, and therapeutic process patient is very painful.
Motherland's medical science has advantage to treatment of chronic prostatitis. The methods such as classical method mainly includes that oral medicinal herb, external application stick, herbal enema and suppository rectally, make a general survey of current treatment thinking and method, taking promoting blood circulation and removing blood stasis, clearing heat and promoting diuresis is treating stranguria, kidney tonifying etc. is generally used as treatment rule in the treatment of clinical chronic prostatitis. And Chinese medicine prostatitis, has the advantages such as cheap and easy to get, bad reaction is little, therefore becomes one of current study hotspot and trend.
Summary of the invention
Modern medicine is thought, in the pathogenesis of chronic non-bacterial prostatitis and prostatic special anatomical structure, rear urethral smooth muscle spasm, prostate urine instead flow, the factor analysis such as cytokine mediated immune response, wherein Cytokine is further remarkable. The inventor, on the basis of cell factor theory, uses the method for motherland's medical science, has found the new method of a treatment chronic non-bacterial prostatitis. Based on this methods for the treatment of, the object of the present invention is to provide a kind of Chinese medicine composition and application thereof of resistance prostatitis.
In order to realize object of the present invention, inventor studies and persistent exploration by lot of experiments, has finally obtained following technical scheme:
One is treated prostatitic Chinese medicine composition, comprise Chinese medical extract and pharmaceutic adjuvant, described Chinese medical extract is prepared from through water extraction and alcohol precipitation method by the traditional Chinese medicinal material raw materials of following weight portion: adenophora tetraphylla 9-15 part, semen brassicae 9-15 part, stone melon seeds 17-24 part, extra large Cassia tora 10-18 part, evening primrose 20-30 part, acute turpinia leaf 20-30 part, conyza blinii 9-15 part, willow leaf 6-10 part.
Preferably, the prostatitic Chinese medicine composition for the treatment of as mentioned above, described Chinese medical extract is prepared from through water extraction and alcohol precipitation method by the traditional Chinese medicinal material raw materials of following weight portion: adenophora tetraphylla 11-13 part, semen brassicae 11-13 part, stone melon seeds 19-21 part, extra large Cassia tora 13-15 part, evening primrose 23-26 part, acute turpinia leaf 23-26 part, conyza blinii 11-13 part, willow leaf 7-9 part.
In a most preferred embodiment of the present invention, Chinese medical extract as above is prepared from through water extraction and alcohol precipitation method by the traditional Chinese medicinal material raw materials of following weight portion: 12 parts of adenophora tetraphyllas, 12 parts of semen brassicaes, 20 parts, stone melon seeds, 14 parts of extra large Cassia tora, 25 parts of evening primroses, 25 parts of acute turpinia leafs, 12 parts of conyza bliniis, 8 parts of willow leaves.
Preferably, the prostatitic Chinese medicine composition of above-mentioned treatment is oral formulations. Again further preferably, described oral formulations comprises oral liquid, granule, Tablet and Capsula agent.
Above-mentioned each Chinese medicine is prepared into the preparation method of compound granular agent of the present invention, comprise the steps: to take the adenophora tetraphylla 9-15 part cleaning up, semen brassicae 9-15 part, stone melon seeds 17-24 part, sea Cassia tora 10-18 part, evening primrose 20-30 part, acute turpinia leaf 20-30 part, conyza blinii 9-15 part, willow leaf 6-10 part, merge, twice of boiling, collecting decoction, be evaporated to medicinal extract, adding ethanol makes to reach 70-80% (v/v) containing alcohol amount, stir, leave standstill, filter, when filtrate decompression is condensed into 65 DEG C, relative density is 1.20-1.30, and reclaim ethanol, obtain concentrate, by concentrate freeze drying, pulverized 80 mesh sieves, obtain cream powder clearly, clear cream powder is dropped in trough type mixing machine together with pharmaceutically acceptable auxiliary material, stir, slowly add while stirring adhesive, to making softwood, granulate with 12 order stainless steel sifts, forced air drying under 60 DEG C of conditions, takes out, and cools and obtain granule.
It should be noted that, Chinese medicine composition of the present invention in preparation process, adopt traditional Chinese medicinal material raw materials source as follows: adenophora tetraphylla is selected Campanulaceae adenophora tetraphyllaAdenophoratetraphylla（Thunb.）Fisch.Dry root. Semen brassicae is selected crucifer sinapsis albaSinapisalbaL.Dry seed. Stone melon seeds are selected Asclepiadaceae eye tree nelumbium eye tree lotusDischidiachinensisChamp.exBenth.Dry herb. Sea Cassia tora is selected Trochidae animal Chlorostoma nigerrima (Gmelin)Chlorostomanigerrinma(Gmelin)Shell. Evening primrose is selected Oenotheraceae evening primroseOenotheraerythrosepalaBorbDry root. Acute turpinia leaf is selected the sharp sharp acute turpinia leaf of Staphyleaceae plantTurpiniaarguta（Lindl.）Seem.［OchrantheargutaLindl.］Dry leaf. Conyza blinii is selected the dry herb of the little Artemisia santonica ConyzabliniiLevl. of the false fluffy platymiscium of composite family. Willow leaf is selected Salicaceous Plants weeping willowSalixbabylonicaL.Dry leaf.
The secretion of cell factor is the key factor that tissue is inflamed, and TNF-α and IL-8 proinflammatory gene representation play very important effect in the immunological regulation of body and the pathogenic process of chronic non-bacterial prostatitis. Inflammation can produce TNF-α under the effects such as infection, toxin, wound, these cell factors can increase chemotactic factor (CF) as the expression of IL-8, expression product is caused and damages and cause pain body tissue by mechanism separately, and regulation and control inflammatory factor indirectly inflammation-inhibiting reacts. Therefore the inventor selects TNF-α in prostata tissue, IL-8 level as the contrast index to the treatment of chronic non-bacterial prostatitis rat, found that: compared with sham-operation group, in model control group rat prostate tissue TNF-α and IL-8 level increase (P< 0.01); Compared with model control group, adopt TNF-α and IL-8 level in the treatment group rat prostate tissue of Chinese medical extract intervention of the present invention significantly reduce (P< 0.01). Therefore, the present invention also provides a kind of pharmaceutical applications, that is: the application of above-mentioned Chinese medical extract in the medicine of preparation treatment chronic non-bacterial prostatitis.
Compared with prior art, Chinese medicine composition of the present invention is brought into play the therapeutic action to chronic non-bacterial prostatitis by TNF-α and IL-8 level in reduction patient prostata tissue, reduces inflammatory reaction degree, thereby promotes the reparation of prostata tissue structure.
Detailed description of the invention
Be below Preparation Example and the test of pesticide effectiveness example of Chinese medicine composition of the present invention, technical scheme of the present invention is done to further description, but protection scope of the present invention be not limited to these embodiment.
The preparation of embodiment 1 granule
Get the raw materials ready: adenophora tetraphylla 1.2kg, semen brassicae 1.2kg, stone melon seeds 2.0kg, extra large Cassia tora 1.4kg, evening primrose 2.5kg, acute turpinia leaf 2.5kg, conyza blinii 1.2kg, willow leaf 0.8kg.
Preparation: take the above-mentioned Chinese medicine cleaning up by recipe quantity, merge, pulverize, twice of boiling, add water for the first time as 10 times of amounts of medicinal material weight, decoct 2h, add water for the second time as 8 times of amounts of medicinal material weight, decoct 1h, collecting decoction, 0.07MPa, at 65 DEG C of temperature, be evaporated to relative density and be 1.15 medicinal extract, adding 95% (v/v) ethanol makes to reach 75% (v/v) containing alcohol amount, stir, leave standstill 24 hours, filter, filtrate is at 0.07MPa, under 65 DEG C of conditions reduced pressure concentration become to relative density be 1.25, and reclaim ethanol, obtain concentrate, by concentrate freeze drying, dry thing was pulverized 80 mesh sieves, obtain cream powder clearly, claim qinghuo reagent powder 10g, lactose 80g, microcrystalline cellulose 80g, sodium carboxymethylcellulose 15g, drop in trough type mixing machine, stir 20 minutes, slowly add while stirring 55% ethanol (ethanol water that volumetric concentration is 55%), to making softwood, granulate with 12 order stainless steel sifts, forced air drying under 60 DEG C of conditions, takes out, cool and obtain granule, by every bag of 10g packaging.
The preparation of embodiment 2 granules
Get the raw materials ready: adenophora tetraphylla 1.5kg, semen brassicae 1.2kg, stone melon seeds 1.8kg, extra large Cassia tora 1.8kg, evening primrose 2.0kg, acute turpinia leaf 3.0kg, conyza blinii 1.0kg, willow leaf 1.0kg.
Preparation: take the above-mentioned traditional Chinese medicinal material raw materials cleaning up by recipe quantity, merge, pulverize, twice of boiling, add water for the first time as 10 times of amounts of medicinal material weight, decoct 2h, add water for the second time as 8 times of amounts of medicinal material weight, decoct 1h, collecting decoction, 0.07MPa, at 65 DEG C, be evaporated to relative density and be 1.15 medicinal extract, adding 95% (v/v) ethanol makes to reach 75% (v/v) containing alcohol amount, stir, leave standstill 24 hours, filter, filtrate is at 0.07MPa, under 65 DEG C of conditions reduced pressure concentration become to relative density be 1.25, and reclaim ethanol, obtain concentrate, by concentrate freeze drying, pulverized 80 mesh sieves, obtain cream powder clearly, claim qinghuo reagent powder 10g, lactose 80g, microcrystalline cellulose 80g, sodium carboxymethylcellulose 15g, drop in trough type mixing machine, stir 20 minutes, slowly add while stirring 55% ethanol (ethanol water that volumetric concentration is 55%), to making softwood, granulate with 12 order stainless steel sifts, forced air drying under 60 DEG C of conditions, takes out, cool and obtain granule, by every bag of 10g packaging.
The clinical trial research of embodiment 3 Chinese herbal granules to chronic non-bacterial prostatitis rat model
2 month female SD rat 6O, initial weight 210-250g, ad lib, drinking-water also keep 12h light and shade to replace illumination, 18～25 DEG C of indoor temperatures, humidity 45%-65%, well-ventilated, adapts to 1 week at this feeding environment before experiment. Adopt table of random number method to be only divided into model control group, treatment group and the each 2O of sham-operation group. Take after lumbar injection 10% chloral hydrate anesthesia rat, under aseptic condition in lower abdomen median incision, expose both sides seminal vesicle and prostate, rats in sham-operated group in lateral lobe of prostate gland injecting normal saline 0.2mL/ only, all the other rats are injected to respectively lateral lobe of prostate gland with 25% XIAOZHILING ZHUSHEYE 0.2mL, close abdomen. After 5 weeks, can form chronic non-bacterial prostatitis model. Pathological change is inflammatory cell infiltration in body of gland, and secretion reduces, and lumen of gland blocks, dwindles, interstitial fibrosis. Postoperative the 5th day each group start the correspondingly tested material of the following dosage of gavage: model control group is physiological saline 10mL/kg; Sham-operation group is physiological saline 10mL/kg; Treatment group is that the clear cream powder of clear cream powder 0.75g/kg(prepared by embodiment 1 is dissolved in physiological saline). Respectively organize all by 1 time/d administration totally 5 weeks.
After last administration 60min, disconnected rat neck is put to death, isolate prostata tissue, shred, the ratio that adds physiological saline 400 μ L in every 100mg prostata tissue mixes. Draw 20 μ L suspensions, add white blood cell count(WBC) liquid 0.38mL, mix, fill pond, on cell counting count board, count four jiaos of total white blood cellses in 4 large grids. ELISA kit detects TNF-α, IL-8 expression in rat blood serum and prostata tissue homogenate.
Administration finishes the ordinary circumstance of rear observation rat, model control group rat and rats in sham-operated group comparison, movable minimizing, hypotrichosis tarnish; Treatment group rat and the comparison of model control group rat, hair is relatively glossy, and ordinary circumstance still can. In modeling process, 1 for the treatment of group unexpected death, dead 2 of model control group.
In addition, respectively organize in rat prostate tissue TNF-α and the horizontal statistics of IL-8 in table 1. Result of the test by table 1 can find out, compared with sham-operation group, in model control group rat prostate tissue TNF-α and IL-8 level increase (P< 0.01). Compared with model control group, treatment group rat TNF-α and IL-8 level significantly reduce (P＜0.01)。
TNF-α and the comparison of IL-8 level in the each group of table 1 rat prostate tissue
| Group | Sample size | TNF-α（ng/L） | IL-8（ng/L） |
| Sham-operation group | 20 | 3.71±0.46 | 24.15±2.94 |
| Model control group | 18 | 149.28±1.02★★ | 98.20±17.33★★ |
| Treatment group | 19 | 12.40±1.69▼▼ | 37.09±5.18▼▼ |
Model control group and the comparison of sham-operation group,★ P＜0.05；★★ P< 0.01; Treatment group and model control group comparison,▼ P＜0.05，▼▼ P＜0.01。
Each group rat leukocyte counting statistics the results are shown in Table 2. Test statistics result by table 2 can find out, sham-operation group is starkly lower than other two groups; The quantity of leucocyte for the treatment of group significantly declines, with model control group relatively have significant difference (P＜0.01)。
Table 2 each group rat leukocyte and serium inorganic phosphorus lipophore are counted comparison
| Group | Sample size | Leucocyte (109Individual) |
| Sham-operation group | 20 | 1.80±0.21 |
| Model control group | 18 | 9.49±1.13★★ |
| Treatment group | 19 | 4.37±0.66▼▼ |
Model control group and the comparison of sham-operation group,★ P＜0.05；★★ P＜0.01；
Treatment group and model control group comparison,▼ P＜0.05，▼▼ P＜0.01。
Claims (3)
1. the prostatitic Chinese medicine composition for the treatment of, comprise Chinese medical extract and pharmaceutic adjuvant, it is characterized in that: described Chinese medical extract is prepared from through water extraction and alcohol precipitation method by the traditional Chinese medicinal material raw materials of following weight portion: 15 parts of adenophora tetraphyllas, 12 parts of semen brassicaes, 18 parts, stone melon seeds, 18 parts of extra large Cassia tora, 20 parts of evening primroses, 30 parts of acute turpinia leafs, 10 parts of conyza bliniis, 10 parts of willow leaves.
2. treat according to claim 1 prostatitic Chinese medicine composition, it is characterized in that: described Chinese medicine composition is oral formulations, described oral formulations is oral liquid, granule, tablet or capsule.
3. treat according to claim 1 prostatitic Chinese medicine composition, it is characterized in that described Chinese medicinal composition granules is made by following processing step: take by weight the following traditional Chinese medicinal material raw materials cleaning up: adenophora tetraphylla, semen brassicae, stone melon seeds, extra large Cassia tora, evening primrose, acute turpinia leaf, conyza blinii, willow leaf; Merge, pulverize, boiling twice, adds water for the first time as 10 times of amounts of medicinal material weight, decocts 2h, add water for the second time as 8 times of amounts of medicinal material weight, decoct 1h, collecting decoction, is evaporated to relative density and is 1.15 medicinal extract at 0.07MPa, 65 DEG C of temperature, adding 95%v/v ethanol makes to reach 75%v/v containing alcohol amount, stir, leave standstill 24 hours, filter, filtrate reduced pressure concentration under 0.07MPa, 65 DEG C of conditions become to relative density be 1.25, and reclaim ethanol, obtain concentrate, by concentrate freeze drying, dry thing was pulverized 80 mesh sieves, obtained cream powder clearly; Claim qinghuo reagent powder 10g, lactose 80g, microcrystalline cellulose 80g, sodium carboxymethylcellulose 15g, drop in trough type mixing machine, stir 20 minutes, slowly adding while stirring volumetric concentration is 55% ethanol water, to making softwood, with 12 order stainless steel sifts granulations, forced air drying under 60 DEG C of conditions, takes out, and cools and obtain granule.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410461218.7A CN104173547A (en) | 2014-09-12 | 2014-09-12 | Traditional Chinese medicine composition for treating prostatitis and application thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410461218.7A Division CN104173547A (en) | 2014-09-12 | 2014-09-12 | Traditional Chinese medicine composition for treating prostatitis and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105582134A true CN105582134A (en) | 2016-05-18 |
Family
ID=51955071
Family Applications (10)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610145710.2A Withdrawn CN105582133A (en) | 2014-09-12 | 2014-09-12 | Traditional Chinese medicine composition for treating prostatitis |
| CN201610149899.2A Withdrawn CN105687438A (en) | 2014-09-12 | 2014-09-12 | Method for preparing traditional Chinese medicine composition for treating prostatitis |
| CN201610145713.6A Withdrawn CN105582134A (en) | 2014-09-12 | 2014-09-12 | Traditional Chinese medicine composition for treating prostatitis |
| CN201610020122.6A Withdrawn CN105412320A (en) | 2014-09-12 | 2014-09-12 | Application of traditional Chinese medicine extract in preparation of medicine for treating chronic abacterial prostatitis |
| CN201610020124.5A Withdrawn CN105412321A (en) | 2014-09-12 | 2014-09-12 | Method for preparing traditional Chinese medicine composition granules for treating prostatitis |
| CN201610145694.7A Withdrawn CN105687437A (en) | 2014-09-12 | 2014-09-12 | Traditional Chinese medicine composition for treating prostatitis |
| CN201610150077.6A Withdrawn CN105582136A (en) | 2014-09-12 | 2014-09-12 | Application of traditional Chinese medicine extract in preparation of medicine for treating prostatitis |
| CN201610149975.XA Withdrawn CN105582135A (en) | 2014-09-12 | 2014-09-12 | Application of traditional Chinese medicine extract in preparation of medicine for treating prostatitis |
| CN201610149971.1A Withdrawn CN105535215A (en) | 2014-09-12 | 2014-09-12 | Method of preparing traditional Chinese medicine composition for treating prostatitis |
| CN201410461218.7A Pending CN104173547A (en) | 2014-09-12 | 2014-09-12 | Traditional Chinese medicine composition for treating prostatitis and application thereof |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610145710.2A Withdrawn CN105582133A (en) | 2014-09-12 | 2014-09-12 | Traditional Chinese medicine composition for treating prostatitis |
| CN201610149899.2A Withdrawn CN105687438A (en) | 2014-09-12 | 2014-09-12 | Method for preparing traditional Chinese medicine composition for treating prostatitis |
Family Applications After (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610020122.6A Withdrawn CN105412320A (en) | 2014-09-12 | 2014-09-12 | Application of traditional Chinese medicine extract in preparation of medicine for treating chronic abacterial prostatitis |
| CN201610020124.5A Withdrawn CN105412321A (en) | 2014-09-12 | 2014-09-12 | Method for preparing traditional Chinese medicine composition granules for treating prostatitis |
| CN201610145694.7A Withdrawn CN105687437A (en) | 2014-09-12 | 2014-09-12 | Traditional Chinese medicine composition for treating prostatitis |
| CN201610150077.6A Withdrawn CN105582136A (en) | 2014-09-12 | 2014-09-12 | Application of traditional Chinese medicine extract in preparation of medicine for treating prostatitis |
| CN201610149975.XA Withdrawn CN105582135A (en) | 2014-09-12 | 2014-09-12 | Application of traditional Chinese medicine extract in preparation of medicine for treating prostatitis |
| CN201610149971.1A Withdrawn CN105535215A (en) | 2014-09-12 | 2014-09-12 | Method of preparing traditional Chinese medicine composition for treating prostatitis |
| CN201410461218.7A Pending CN104173547A (en) | 2014-09-12 | 2014-09-12 | Traditional Chinese medicine composition for treating prostatitis and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (10) | CN105582133A (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105434982A (en) * | 2015-12-22 | 2016-03-30 | 青岛市市立医院 | Chronic nonbacterial prostatitis treating pharmaceutical composition |
| EP3342407A1 (en) * | 2017-01-03 | 2018-07-04 | Dompé farmaceutici S.p.A. | Il-8 inihibitors for use in the treatment of some urological disorders |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101695555B (en) * | 2008-11-13 | 2011-05-18 | 赵子山 | Medicament composition for treating prostatitis and prostatomegaly and preparation method thereof |
| CN102379965A (en) * | 2011-08-14 | 2012-03-21 | 北京绿源求证科技发展有限责任公司 | Traditional Chinese medicine for treating chronic prostatitis |
-
2014
- 2014-09-12 CN CN201610145710.2A patent/CN105582133A/en not_active Withdrawn
- 2014-09-12 CN CN201610149899.2A patent/CN105687438A/en not_active Withdrawn
- 2014-09-12 CN CN201610145713.6A patent/CN105582134A/en not_active Withdrawn
- 2014-09-12 CN CN201610020122.6A patent/CN105412320A/en not_active Withdrawn
- 2014-09-12 CN CN201610020124.5A patent/CN105412321A/en not_active Withdrawn
- 2014-09-12 CN CN201610145694.7A patent/CN105687437A/en not_active Withdrawn
- 2014-09-12 CN CN201610150077.6A patent/CN105582136A/en not_active Withdrawn
- 2014-09-12 CN CN201610149975.XA patent/CN105582135A/en not_active Withdrawn
- 2014-09-12 CN CN201610149971.1A patent/CN105535215A/en not_active Withdrawn
- 2014-09-12 CN CN201410461218.7A patent/CN104173547A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN105582135A (en) | 2016-05-18 |
| CN104173547A (en) | 2014-12-03 |
| CN105412320A (en) | 2016-03-23 |
| CN105687437A (en) | 2016-06-22 |
| CN105582133A (en) | 2016-05-18 |
| CN105535215A (en) | 2016-05-04 |
| CN105582136A (en) | 2016-05-18 |
| CN105687438A (en) | 2016-06-22 |
| CN105412321A (en) | 2016-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101947284B (en) | Traditional Chinese medicinal composition for treating diabetes and preparation method thereof | |
| CN102488848B (en) | Traditional Chinese medicine composition used for treating high-pathogenicity porcine reproductive and respiratory syndrome, preparation method thereof, and application thereof | |
| CN102552580A (en) | Formula of orally-taken drug for treating lithangiuria and difficult urination and preparation technology of drug | |
| CN101884749B (en) | Particle for eliminating turbidity and treating arthralgia | |
| CN105213974A (en) | One treats lymphadenomatous Chinese medicine composition and application thereof | |
| CN105582134A (en) | Traditional Chinese medicine composition for treating prostatitis | |
| CN103191282B (en) | Traditional Chinese medicinal composition for treating fever in children as well as preparation method and application thereof | |
| CN103735710B (en) | Traditional Chinese medicine composition for treating recessive mastitis of dairy cows and preparation method thereof | |
| CN102240352A (en) | Narcotic powder for tooth extraction and preparation method thereof | |
| CN105770691A (en) | Medicinal preparation for treating cervical cancer and application thereof | |
| CN104800464A (en) | Traditional Chinese medicine for treating urticaria | |
| CN104337901A (en) | Chinese medicinal preparation for treating nonspecific cystitis and preparation method thereof | |
| CN104306585B (en) | One kind is used to treat prostatitic Chinese medicine composition and preparation method and application | |
| CN105663380A (en) | Method for preparing traditional Chinese medicine composition for treating prostatitis | |
| CN105663381A (en) | Application of Chinese herb extract to preparation of drug for treating prostatitis | |
| CN106237206A (en) | A kind of Chinese medicine preparation treating tumor and preparation method thereof | |
| CN104815131A (en) | Pharmaceutical composition for treating chicken gout and preparation method thereof | |
| CN105497459A (en) | Traditional Chinese medicine preparation for treating woman leukorrheal diseases as well as preparation method and application of traditional Chinese medicine preparation | |
| CN102961678B (en) | Traditional Chinese medicine preparation for treating gallstone and cholecystitis and preparation method thereof | |
| CN105412679A (en) | Traditional Chinese medicine preparation for treating lung abscess and preparation method thereof | |
| CN105311578A (en) | Traditional Chinese medicine composition for treating intracranial tumors | |
| CN104958704A (en) | Pharmaceutical composition for treating bovine endometritis and preparation method of pharmaceutical composition | |
| CN108938952A (en) | A kind of pharmaceutical composition and preparation method thereof for treating calculus | |
| CN104689073A (en) | Medicine for treating yin deficiency and heat-poison type lung cancer and preparation method thereof | |
| CN102961677B (en) | Traditional Chinese medicine preparation for treating gallstone and cholecystitis and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20160518 |